vimarsana.com

Page 257 - லண்டன் பள்ளி ஆஃப் சுகாதாரம் வெப்பமண்டல மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lagos traffic creating life or death situations for women trying to reach hospital – report

The study collected data from 738 pregnant women who arrived at four of Lagos’s largest public hospitals with life-threatening complications. Estimating their travel time using computer models and online maps, researchers sent out drivers to reconstruct their journeys and found that travel times were one and a half times longer than Google maps predicted, and four times longer than computer models. “There are huge life and death implications of travel time to reach facilities for pregnant women in emergency situations,” said LSE’s Dr Aduragbemi Banke-Thomas. “The World Health Organization recommends that women should be able to access health facilities within two hours,” he said, pointing out that online models all suggested they had, but that was not the case.

Russia s Sputnik V vaccine 91 6% effective in late-stage trial – The Zimbabwe Mail

Russia s Sputnik V MOSCOW (Reuters) – Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing COVID-19, according to peer-reviewed results from its late-stage clinical trial published in The Lancent international medical journal on Tuesday. Scientists said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released. The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.

Russia s Covid vaccine shows over 91% efficacy in phase 3 trial: Lancet

Russia s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday. The findings are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo. Serious adverse events or those requiring hospital admission were rare in both the placebo and vaccine groups and none were considered associated with vaccination, the researchers said. Four deaths were reported in the trial, none of which were considered related to the vaccine, they said, adding most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy.

Russia s Sputnik V COVID-19 vaccine shows 91 6% efficacy in late-stage trial

Russia’s Sputnik V COVID-19 vaccine shows 91.6% efficacy in late-stage trial MarketWatch 2/2/2021 © oliver bunic/Agence France-Presse/Getty Images Russia’s Sputnik V vaccine shows 91.6% efficacy against symptomatic coronavirus, according to results from its late-stage clinical trial published in medical journal The Lancet on Tuesday. The preliminary findings, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, are based on data gathered from 19,866 participants, of which around three-quarters received two doses of the vaccine and a quarter were given a placebo. There were 16 cases of COVID-19 in the vaccine group in the 21 days after the first dose, and 62 cases of the disease in the placebo group, equating to an efficacy of 91.6%, the researchers wrote in The Lancet.

Coronavirus vaccine LIVE UPDATES: Russian Sputnik jab shown to be 91 6pc effective

Natasha Rudra, Natasha Boddy Melbourne is on high alert after a quarantine worker linked to the Australian Open tested positive for COVID-19, sparking fears of an outbreak. Premier Daniel Andrews has re-introduced snap restrictions on the city that come into effect at midnight Thursday, including mandatory masks indoors and a reduction in the number of people allowed to gather in private. The 26-year-old man from Noble Park worked as a resident support officer at the Grand Hyatt Hotel in Melbourne, as part of the Australian Open quarantine program. Like many quarantine workers, he was tested every day, and was negative on his last day of work, January 29. He subsequently developed symptoms and tested positive today.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.